Can anything shut down the Gold rally?
VANCOUVER - Carolyn Cross, a major shareholder of Ondine Biomedical Inc., has reduced her voting rights in the company to 23.01% from 26.72%, according to a regulatory filing released Thursday.
The threshold change occurred on September 3, 2025, as detailed in a notification of major holdings submitted to the Financial Conduct Authority.
Cross now directly holds 66,600,930 voting rights, representing 12.85% of the company, while indirectly controlling an additional 52,657,292 voting rights (10.16%) through controlled entities.
The filing shows that 0902337 B.C. Ltd., a company controlled by Cross, holds 9.43% of the voting rights in Ondine Biomedical.
The notification indicates that Cross does not hold any financial instruments related to the company’s shares. The total number of voting rights held by Cross now stands at 119,258,222.
Ondine Biomedical, a non-UK issuer, made the disclosure through a regulatory news service filing as required by transparency regulations for companies with shares traded on public exchanges.
The information was based on a standard form for notification of major holdings submitted by the shareholder.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.